184 related articles for article (PubMed ID: 20463415)
1. Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome.
Mehta A
Postgrad Med; 2010 May; 122(3):61-70. PubMed ID: 20463415
[TBL] [Abstract][Full Text] [Related]
2. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
Turhan H; Yetkin E
Int J Cardiol; 2006 Jun; 110(2):276-7. PubMed ID: 16364471
[TBL] [Abstract][Full Text] [Related]
3. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.
Ginsberg HN; Stalenhoef AF
J Cardiovasc Risk; 2003 Apr; 10(2):121-8. PubMed ID: 12668909
[TBL] [Abstract][Full Text] [Related]
4. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Davidson M
Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
[TBL] [Abstract][Full Text] [Related]
5. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
6. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
[No Abstract] [Full Text] [Related]
7. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
Kastelein JJ
Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
[TBL] [Abstract][Full Text] [Related]
8. Metabolic syndrome: is it a syndrome? Does it matter?
Kahn R
Circulation; 2007 Apr; 115(13):1806-10; discussion 1811. PubMed ID: 17404171
[No Abstract] [Full Text] [Related]
9. [Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates].
Cybulska B; Kłosiewicz-Latoszek L
Kardiol Pol; 2005 Jun; 62 Suppl 2():II45-50. PubMed ID: 19813336
[No Abstract] [Full Text] [Related]
10. On the road to better dyslipidemia outcomes.
Hughes S
Nurse Pract; 2009 Feb; 34(2):14-21; quiz 22. PubMed ID: 19155874
[No Abstract] [Full Text] [Related]
11. Controversies in dyslipidemias: atheroprevention in diabetes and insulin resistance.
Brinton EA
Ann N Y Acad Sci; 2005 Dec; 1055():159-78. PubMed ID: 16387723
[TBL] [Abstract][Full Text] [Related]
12. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Adiels M; Olofsson SO; Taskinen MR; Borén J
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome: diabetes and cardiovascular disease.
Gupta S; Gupta BM
Indian Heart J; 2006; 58(2):149-52. PubMed ID: 18989060
[TBL] [Abstract][Full Text] [Related]
14. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Wierzbicki AS
Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
[TBL] [Abstract][Full Text] [Related]
15. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance.
Kendall DM; Harmel AP
Am J Manag Care; 2002 Dec; 8(20 Suppl):S635-53; quiz S654-7. PubMed ID: 12510788
[TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations.
Zarich SW
Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752
[TBL] [Abstract][Full Text] [Related]
17. [On behalf and the extent of evidence].
Ruiz J
Rev Med Suisse; 2010 Jun; 6(252):1171-2. PubMed ID: 20614750
[No Abstract] [Full Text] [Related]
18. Role for fibrate therapy in diabetes: evidence before FIELD.
Vergès B
Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
[TBL] [Abstract][Full Text] [Related]
19. Is it time to stop treating dyslipidaemia with fibrates?
Benatar JR; Stewart RA
N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928
[TBL] [Abstract][Full Text] [Related]
20. The metabolic syndrome: prevalence, CHD risk, and treatment.
Sarti C; Gallagher J
J Diabetes Complications; 2006; 20(2):121-32. PubMed ID: 16504841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
